414 related articles for article (PubMed ID: 17002290)
1. Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediates.
Totir MA; Padayatti PS; Helfand MS; Carey MP; Bonomo RA; Carey PR; van den Akker F
Biochemistry; 2006 Oct; 45(39):11895-904. PubMed ID: 17002290
[TBL] [Abstract][Full Text] [Related]
2. High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 {beta}-lactamase.
Padayatti PS; Helfand MS; Totir MA; Carey MP; Carey PR; Bonomo RA; van den Akker F
J Biol Chem; 2005 Oct; 280(41):34900-7. PubMed ID: 16055923
[TBL] [Abstract][Full Text] [Related]
3. Different intermediate populations formed by tazobactam, sulbactam, and clavulanate reacting with SHV-1 beta-lactamases: Raman crystallographic evidence.
Kalp M; Totir MA; Buynak JD; Carey PR
J Am Chem Soc; 2009 Feb; 131(6):2338-47. PubMed ID: 19161282
[TBL] [Abstract][Full Text] [Related]
4. Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitors.
Helfand MS; Taracila MA; Totir MA; Bonomo RA; Buynak JD; van den Akker F; Carey PR
Biochemistry; 2007 Jul; 46(29):8689-99. PubMed ID: 17595114
[TBL] [Abstract][Full Text] [Related]
5. Tazobactam forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV-1 beta-lactamase: 1.63 A crystal structure.
Padayatti PS; Helfand MS; Totir MA; Carey MP; Hujer AM; Carey PR; Bonomo RA; van den Akker F
Biochemistry; 2004 Feb; 43(4):843-8. PubMed ID: 14744126
[TBL] [Abstract][Full Text] [Related]
6. Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallography.
Helfand MS; Totir MA; Carey MP; Hujer AM; Bonomo RA; Carey PR
Biochemistry; 2003 Nov; 42(46):13386-92. PubMed ID: 14621983
[TBL] [Abstract][Full Text] [Related]
7. Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamase.
Totir MA; Helfand MS; Carey MP; Sheri A; Buynak JD; Bonomo RA; Carey PR
Biochemistry; 2007 Aug; 46(31):8980-7. PubMed ID: 17630699
[TBL] [Abstract][Full Text] [Related]
8. Inhibitor-resistant class A beta-lactamases: consequences of the Ser130-to-Gly mutation seen in Apo and tazobactam structures of the SHV-1 variant.
Sun T; Bethel CR; Bonomo RA; Knox JR
Biochemistry; 2004 Nov; 43(44):14111-7. PubMed ID: 15518561
[TBL] [Abstract][Full Text] [Related]
9. Penam sulfones and β-lactamase inhibition: SA2-13 and the importance of the C2 side chain length and composition.
Rodkey EA; Winkler ML; Bethel CR; Pagadala SR; Buynak JD; Bonomo RA; van den Akker F
PLoS One; 2014; 9(1):e85892. PubMed ID: 24454944
[TBL] [Abstract][Full Text] [Related]
10. The importance of the trans-enamine intermediate as a β-lactamase inhibition strategy probed in inhibitor-resistant SHV β-lactamase variants.
Ke W; Rodkey EA; Sampson JM; Skalweit MJ; Sheri A; Pagadala SR; Nottingham MD; Buynak JD; Bonomo RA; van den Akker F
ChemMedChem; 2012 Jun; 7(6):1002-8. PubMed ID: 22438274
[TBL] [Abstract][Full Text] [Related]
11. New Conformations of Acylation Adducts of Inhibitors of β-Lactamase from Mycobacterium tuberculosis.
Tassoni R; Blok A; Pannu NS; Ubbink M
Biochemistry; 2019 Feb; 58(7):997-1009. PubMed ID: 30632739
[TBL] [Abstract][Full Text] [Related]
12. Rational design of a beta-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 A crystal structure of wt SHV-1 complex with a penam sulfone.
Padayatti PS; Sheri A; Totir MA; Helfand MS; Carey MP; Anderson VE; Carey PR; Bethel CR; Bonomo RA; Buynak JD; van den Akker F
J Am Chem Soc; 2006 Oct; 128(40):13235-42. PubMed ID: 17017804
[TBL] [Abstract][Full Text] [Related]
13. Why the extended-spectrum beta-lactamases SHV-2 and SHV-5 are "hypersusceptible" to mechanism-based inhibitors.
Kalp M; Bethel CR; Bonomo RA; Carey PR
Biochemistry; 2009 Oct; 48(41):9912-20. PubMed ID: 19736945
[TBL] [Abstract][Full Text] [Related]
14. The Drug-Resistant Variant P167S Expands the Substrate Profile of CTX-M β-Lactamases for Oxyimino-Cephalosporin Antibiotics by Enlarging the Active Site upon Acylation.
Patel MP; Hu L; Stojanoski V; Sankaran B; Prasad BVV; Palzkill T
Biochemistry; 2017 Jul; 56(27):3443-3453. PubMed ID: 28613873
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the SHV-1 beta-lactamase by sulfones: crystallographic observation of two reaction intermediates with tazobactam.
Kuzin AP; Nukaga M; Nukaga Y; Hujer A; Bonomo RA; Knox JR
Biochemistry; 2001 Feb; 40(6):1861-6. PubMed ID: 11327849
[TBL] [Abstract][Full Text] [Related]
16. X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 beta-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid.
Swarén P; Golemi D; Cabantous S; Bulychev A; Maveyraud L; Mobashery S; Samama JP
Biochemistry; 1999 Jul; 38(30):9570-6. PubMed ID: 10423234
[TBL] [Abstract][Full Text] [Related]
17. Why clinically used tazobactam and sulbactam are poor inhibitors of OXA-10 beta-lactamase: Raman crystallographic evidence.
Totir MA; Cha J; Ishiwata A; Wang B; Sheri A; Anderson VE; Buynak J; Mobashery S; Carey PR
Biochemistry; 2008 Apr; 47(13):4094-101. PubMed ID: 18324783
[TBL] [Abstract][Full Text] [Related]
18. Theoretical investigation on reaction of sulbactam with wild-type SHV-1 β-lactamase: acylation, tautomerization, and deacylation.
Li R; Liao JM; Gu CR; Wang YT; Chen CL
J Phys Chem B; 2011 Sep; 115(34):10298-310. PubMed ID: 21797222
[TBL] [Abstract][Full Text] [Related]
19. Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.
Papp-Wallace KM; Winkler ML; Taracila MA; Bonomo RA
Antimicrob Agents Chemother; 2015 Jul; 59(7):3710-7. PubMed ID: 25666153
[TBL] [Abstract][Full Text] [Related]
20. Following drug uptake and reactions inside Escherichia coli cells by Raman microspectroscopy.
Heidari Torkabadi H; Bethel CR; Papp-Wallace KM; de Boer PA; Bonomo RA; Carey PR
Biochemistry; 2014 Jul; 53(25):4113-21. PubMed ID: 24901294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
